Qutenza Patent Expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6239180 AVERITAS Transdermal therapeutic device and method with capsaicin and capsaicin analogs
Nov, 2016

(7 years ago)

US10869827 AVERITAS Compositions and kits for the removal of irritating compounds from bodily surfaces
Sep, 2023

(10 months ago)

US8889113 AVERITAS Compositions and kits for the removal of irritating compounds from bodily surfaces
Sep, 2023

(10 months ago)

US10463598 AVERITAS Compositions and kits for the removal of irritating compounds from bodily surfaces
Sep, 2023

(10 months ago)

US8263059 AVERITAS Compositions and kits for the removal of irritating compounds from bodily surfaces
Sep, 2023

(10 months ago)

US10034841 AVERITAS Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer of the system and use of said back layer
Sep, 2025

(1 year, 1 month from now)

US9226903 AVERITAS Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer or the system and use of said back layer
Dec, 2028

(4 years from now)

US8821920 AVERITAS Therapeutic patch for transdermal delivery of capsaicin
Mar, 2030

(5 years from now)



Qutenza is a drug owned by Averitas Pharma Inc. It is used for removing capsaicin from a treatment area or unintended area. Qutenza uses Capsaicin as an active ingredient. Qutenza was launched by Averitas in 2009. It is is available in patch form for topical use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Mar 26, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 16, 2014
Orphan Drug Exclusivity(ODE) Nov 16, 2016
New Indication(I-838) Jul 17, 2023

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using CAPSAICIN ingredient

NCE-1 date: 16 November, 2013

Market Authorisation Date: 16 November, 2009

Treatment: Method of using capsaicin in combination with a gel composition for removal of capsaicin from a treatment area or unintended area

Dosage: PATCH

More Information on Dosage

QUTENZA family patents

Family Patents